On Mar 20, we issued an updated research report on AMN Healthcare Services Inc AMN. The company’s soft Locum Tenens Business and a dull 2019 view are concerning factors at the moment.
Over the past year, the Zacks Rank #4 (Sell) stock has declined 16.5% against its industry’s 15.2% rally. The current level is also lower than the S&P 500 index’s 6.4% gain.
For the first quarter, four estimates have moved down over the last 60 days, compared to no movement in the opposite direction. For 2019, five estimates have moved south.
Reflective of this, AMN Healthcare’s current-quarter earnings per share projection plunged 18.6% to 70 cents over the past two months. Meanwhile, current-year earnings per share estimate moved 33.6% to down $2.98 over the same time frame.
AMN Healthcare Services Inc Price and Consensus
AMN Healthcare Services Inc Price and Consensus | AMN Healthcare Services Inc Quote
What’s Deterring the Stock?
In the recently-reported fourth quarter of 2018, Locum Tenens revenues declined 24% to $82 million, far wider than management’s expectation of a 14% fall. Per management, there were larger-than-expected declines in the emergency medicine and hospital specialties due to a drop in demand. Hence, first-quarter 2019 Locum Tenens revenues are expected to deteriorate year over year.
Furthermore, the company expects 2019 organic revenues to decline 6% owing to expectations of lower contributions from the Locum Tenens business. Additionally, Nurse and Allied segment revenues are expected to decline about 1-2% year over year.
Lastly, AMN Healthcare outsources certain critical applications or business processes to external providers, including cloud-based, credentialing and data processing services. Hence, the failure or inability to perform by one or more of these critical suppliers could cause significant disruptions and raise costs for the company.
However, it is encouraging to note that the company’s acquisition of MedPartners has proven accretive in recent times.
A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN, Veeva Systems VEEV and DexCom. Inc. DXCM. Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s long-term earnings growth rate is expected at 20.9%.
Veeva Systems’ long-term earnings growth rate is estimated at 14.8%.
DexCom’s next-quarter earnings per share are projected to grow 120%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research